Chi Li, Ph.D.

Chi Li, Ph.D.

Institution: University of Louisville Research Foundation, Inc.

Project: Inhibiting Lung Adenocarcinoma Growth by Inducing Apoptosis Independent of Bcl-2 Proteins

Grant(s): Innovation Award

Lung cancer is the leading cause of cancer death in the United States and the world. Lung adenocarcinoma is the most common type of lung cancer, accounting for approximately 40% of lung cancers. The high mortality rate associated with lung adenocarcinoma is partially attributed to ineffective therapeutic treatments. Thus, it is critical to develop new chemotherapeutic drugs for lung adenocarcinoma. Apoptosis, or programmed cell death, is a normal suicidal process the body uses to selectively remove cells that are no longer needed, damaged or are dangerous. Apoptosis is fundamental to our health; failure of cells to die leads to initiation and progression of cancer, and makes cancer cells resistant to anticancer drugs. We will develop a novel therapeutic strategy for lung adenocarcinoma using a molecule called C12, which has been found to induce lung adenocarcinoma programmed cell death in a unique fashion.

The James & Marlene Ryan Innovation Award

Freedom From Smoking Clinic
Toms River, NJ | Dec 07, 2020